Quince Therapeutics, Inc. Common Stock (QNCX) Stock Price
QNCXStock
$30.93−89.73%52W
Market Cap$31.46M
P/E—
PEG Ratio—
Div yield—
Beta1.31
QNCX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.20%
Price vs S&P 500 (4W)69.79%
VGM Score46.37
QNCX Earnings Surprise History
Q2 25-65.02est. -46.50
Q3 25-50.00est. -44.50
Q4 25-152.00est. -45.00
Q1 2657.60est. -52.00
Q2 26-12.15est. -12.39
QNCX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
2.33
2.38
3.92
4.00
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
QNCXQuince Therapeutics, Inc. Common Stock | — | — | C | $30.93 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Quince Therapeutics, Inc. Common Stock
Quince Therapeutics is a preclinical-stage biopharmaceutical company developing a bone-targeting platform designed to deliver therapeutics directly to fracture and disease sites while reducing systemic side effects. The platform can accommodate small molecules, peptides, and large molecules. The company's pipeline includes programs in Ataxia-Telangiectasia and Duchenne Muscular Dystrophy, with expansion potential into additional indications.